Loading...
Loading...
Browse all stories on DeepNewz
VisitInsmed's Brensocatib Achieves Positive Late-Stage Results, Shares Surge 155%, Peaking at +132%
May 28, 2024, 10:39 AM
Insmed announced that its experimental drug, brensocatib, achieved positive topline results in the Phase 3 ASPEN study for treating bronchiectasis. The study met its primary endpoint for both dosage strengths, showing a statistically significant and clinically meaningful reduction in the frequency of respiratory symptoms such as chronic cough. As a result, Insmed's shares surged by 155% in pre-market trading, with a peak increase of 132%. Analysts from Truist project peak unadjusted sales of approximately $4 billion for brensocatib in bronchiectasis, with a potential fair value of around $74 per share. The success of this late-stage study marks a significant milestone for Insmed, positioning brensocatib as a promising treatment for chronic lung diseases.
View original story
Increase by over 50% • 25%
Increase by less than 50% • 25%
Decrease • 25%
Remain stable (±10%) • 25%
Exceed $500 million • 25%
Between $300 million and $500 million • 25%
Between $100 million and $300 million • 25%
Below $100 million • 25%
Phase 4 trial • 25%
Approval in additional markets • 25%
Development of new formulations • 25%
Strategic partnership or collaboration • 25%
Yes • 50%
No • 50%
Below $5 billion • 25%
$5 billion to $10 billion • 25%
$10 billion to $15 billion • 25%
Above $15 billion • 25%
Increase over 20% • 25%
Increase 10-20% • 25%
Decrease 10-20% • 25%
Decrease over 20% • 25%
Above $5 billion • 25%
Below $1 billion • 25%
Between $1 billion and $3 billion • 25%
Between $3 billion and $5 billion • 25%
Between $75 and $100 • 25%
Below $50 • 25%
Above $100 • 25%
Between $50 and $75 • 25%